Anal Cancer

High-grade vulvar, vaginal and anal precancer rates decreased or stabilized after the introduction of the HPV vaccine, according to findings published in the American Journal of Preventive Medicine.

The National Cancer Institute has awarded more than $4 million to a collaboration between three research institutions to evaluate anal cancer screenings in high-risk women previously diagnosed with HPV.

The FDA issued a complete response letter to Incyte indicating it cannot approve the company’s biologics license application that seeks approval of retifanlimab for certain patients with anal cancer.

FDA’s Oncologic Drugs Advisory Committee today voted 13 to 4 to recommend deferral of a regulatory decision on retifanlimab for the treatment of certain patients with squamous cell carcinoma of the anal canal.

Today is International HPV Awareness Day.

The FDA granted priority review to retifanlimab for treatment of certain patients with squamous cell carcinoma of the anal canal, according to the agent’s manufacturer.

The incidence of anal cancer among women and those older than 50 years rose significantly from 2001 to 2016, according to a poster presented at the American College of Gastroenterology annual meeting.

Low-dose pomalidomide was well-tolerated and helped clear high-grade squamous intraepithelial lesions caused by HPV in patients with and without HIV, according to research from the Conference on Retroviruses and Opportunistic Infections.

Electrocautery ablation appeared effective for treatment of anal high-grade squamous intraepithelial lesions among people living with HIV, according to results of a retrospective study published in Cancer.

Rates of squamous cell carcinoma of the anus and related mortality have risen sharply over the past 15 years, according to results of a retrospective study published in Journal of the National Cancer Institute.